Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 60 full-time employees. The company went IPO on 2016-06-03. The firm is engaged in the development and delivery of non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The firm uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is incorporated into a portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT technology is used to effectively and safely treat oncological and non-oncological skin conditions. The SRT-100 is a photon x-ray low-energy SRT system that provides patients with an alternative to surgery for treating NMSC, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with an SRT-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and comprehensive dosimetry parameters.
SRTS stock price ended at $0 on 星期三, after dropping NaN%
On the latest trading day Jun 24, 2026, the stock price of SRTS fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for SRTS decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.